Report: Developing Opportunities within Procter & Gamble, ACADIA Pharmaceuticals, Cree, Umpqua, Westrock, and Globus Medical — Future Expectations, Projections Moving into 2018

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Procter & Gamble Company (NYSE:PG), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cree, Inc. (NASDAQ:CREE), Umpqua Holdings Corporation (NASDAQ:UMPQ), Westrock Company (NYSE:WRK), and Globus Medical, Inc. (NYSE:GMED), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

PG DOWNLOAD: http://MarketSourceResearch.com/register/?so=PG
ACAD DOWNLOAD: http://MarketSourceResearch.com/register/?so=ACAD
CREE DOWNLOAD: http://MarketSourceResearch.com/register/?so=CREE
UMPQ DOWNLOAD: http://MarketSourceResearch.com/register/?so=UMPQ
WRK DOWNLOAD: http://MarketSourceResearch.com/register/?so=WRK
GMED DOWNLOAD: http://MarketSourceResearch.com/register/?so=GMED

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Procter & Gamble Company (NYSE:PG), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Cree, Inc. (NASDAQ:CREE), Umpqua Holdings Corporation (NASDAQ:UMPQ), Westrock Company (NYSE:WRK), and Globus Medical, Inc. (NYSE:GMED) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2017. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

PROCTER & GAMBLE COMPANY (PG) REPORT OVERVIEW

Procter & Gamble's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Procter & Gamble reported revenue of $16,653.00MM vs $16,518.00MM (up 0.82%) and basic earnings per share $1.09 vs $0.99 (up 10.10%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Procter & Gamble reported revenue of $65,058.00MM vs $65,299.00MM (down 0.37%) and basic earnings per share $5.80 vs $3.80 (up 52.63%). Procter & Gamble is expected to report earnings on January 19th, 2018. The report will be for the fiscal period ending December 31st, 2017. According to Zacks Investment Research, based on 11 analysts' forecasts, the consensus EPS forecast for the quarter is $1.07. The reported EPS for the same quarter last year was $1.08. The estimated EPS forecast for the next fiscal year is $4.43 and is expected to report on July 26th, 2018.

To read the full Procter & Gamble Company (PG) report, download it here: http://MarketSourceResearch.com/register/?so=PG

-----------------------------------------

ACADIA PHARMACEUTICALS INC. (ACAD) REPORT OVERVIEW

ACADIA Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, ACADIA Pharmaceuticals reported revenue of $35.58MM vs $5.27MM (up 575.36%) and basic earnings per share -$0.53 vs -$0.61. For the twelve months ended December 31st, 2016 vs December 31st, 2015, ACADIA Pharmaceuticals reported revenue of $17.33MM vs $0.06MM (up 28,311.48%) and basic earnings per share -$2.34 vs -$1.63. ACADIA Pharmaceuticals is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.65. The estimated EPS forecast for the next fiscal year is -$1.62 and is expected to report on February 27th, 2018.

To read the full ACADIA Pharmaceuticals Inc. (ACAD) report, download it here: http://MarketSourceResearch.com/register/?so=ACAD

-----------------------------------------

CREE, INC. (CREE) REPORT OVERVIEW

Cree's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Cree reported revenue of $360.40MM vs $371.23MM (down 2.92%) and basic earnings per share -$0.20 vs $0.01. For the twelve months ended June 30th, 2017 vs June 30th, 2016, Cree reported revenue of $1,473.00MM vs $1,616.63MM (down 8.88%) and basic earnings per share -$1.00 vs -$0.21. Cree is expected to report earnings on January 23rd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.09. The estimated EPS forecast for the next fiscal year is -$0.02 and is expected to report on August 28th, 2018.

To read the full Cree, Inc. (CREE) report, download it here: http://MarketSourceResearch.com/register/?so=CREE

-----------------------------------------

UMPQUA HOLDINGS CORPORATION (UMPQ) REPORT OVERVIEW

Umpqua's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Umpqua reported interest income of $240.72MM vs $226.42MM (up 6.31%) and basic earnings per share $0.28 vs $0.28 (unchanged). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Umpqua reported interest income of $910.64MM vs $929.87MM (down 2.07%) and basic earnings per share $1.06 vs $1.01 (up 4.95%). Umpqua is expected to report earnings on January 24th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.27. The estimated EPS forecast for the next fiscal year is $1.23 and is expected to report on January 24th, 2018.

To read the full Umpqua Holdings Corporation (UMPQ) report, download it here: http://MarketSourceResearch.com/register/?so=UMPQ

-----------------------------------------

WESTROCK COMPANY (WRK) REPORT OVERVIEW

Westrock's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Westrock reported revenue of $4,060.60MM vs $3,611.70MM (up 12.43%) and basic earnings per share $0.78 vs -$0.39. For the twelve months ended September 30th, 2017 vs September 30th, 2016, Westrock reported revenue of $14,859.70MM vs $14,171.80MM (up 4.85%) and basic earnings per share $2.81 vs -$1.56. Westrock is expected to report earnings on January 23rd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.47. The estimated EPS forecast for the next fiscal year is $4.22 and is expected to report on November 1st, 2018.

To read the full Westrock Company (WRK) report, download it here: http://MarketSourceResearch.com/register/?so=WRK

-----------------------------------------

GLOBUS MEDICAL, INC. (GMED) REPORT OVERVIEW

Globus Medical's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Globus Medical reported revenue of $151.74MM vs $135.65MM (up 11.86%) and basic earnings per share $0.27 vs $0.27 (unchanged). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Globus Medical reported revenue of $563.99MM vs $544.75MM (up 3.53%) and basic earnings per share $1.09 vs $1.19 (down 8.40%). Globus Medical is expected to report earnings on February 26th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.31. The estimated EPS forecast for the next fiscal year is $1.37 and is expected to report on February 26th, 2018.

To read the full Globus Medical, Inc. (GMED) report, download it here: http://MarketSourceResearch.com/register/?so=GMED

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that help serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that’s ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.